PATRICIA OLIVEIRA GUIMARAES
Projetos de Pesquisa
Unidades Organizacionais
17 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 17
conferenceObject Aspirin- Free Prasugrel Monotherapy: 30-Day Clinical Outcome After Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non- ST-Segment Elevation Acute Coronary Syndrome(2023) NAKAZAWA, Gaku; MIYASHITA, Kotaro; MASUDA, Shinichiro; TOBE, Akihiro; LEMOS, Pedro; GUIMARAES, Patricia; MURAMATSU, Takashi; KOTOKU, Nozomi; KAGEYAMA, Shigetaka; NINOMIYA, Kai; TANABE, Kengo; OZAKI, Yukio; KOZUMA, Ken; ONUMA, Yoshinobu; SERRUYS, PatrickbookPart Ultilização de marca-passo transcutâneo(2015) GUIMARãES, Patrícia Oliveira; SOEIRO, Alexandre de MatosbookPart Utilização de marca-passo transcutâneo(2015) GUIMARãES, Patrícia Oliveira; SOEIRO, Alexandre de Matos- REPLY: Elimination of Aspirin From PCI Pharmacotherapy(2021) LEMOS, Pedro A.; KOGAME, Norihiro; GUIMARAES, Patricia O.; MODOLO, Rodrigo; SERRUYS, Patrick W.
- Patients with COVID-19 who experience a myocardial infarction have complex coronary morphology and high in-hospital mortality: Primary results of a nationwide angiographic study(2021) ABIZAID, Alexandre; CAMPOS, Carlos M.; GUIMARAES, Patricia O.; JR, Jose de Ribamar Costa; FALCAO, Breno A. A.; MANGIONE, Fernanda; CAIXETA, Adriano; LEMOS, Pedro A.; BRITO, Fabio S. de; CAVALCANTE, Ricardo; BEZERRA, Cristiano Guedes; CORTES, Leandro; RIBEIRO, Henrique B.; SOUZA, Francis R. de; HUEMER, Natassja; VAL, Renata M. do; CARAMELLI, Bruno; CALDERARO, Daniela; LIMA, Felipe G.; HAJJAR, Ludhmila A.; MEHRAN, Roxana; KALIL FILHO, RobertoObjectives We aimed to explore angiographic patterns and in-hospital outcomes of patients with concomitant coronavirus disease-19 (COVID-19) and myocardial infarction (MI). Background Patients with COVID-19 may experience MI during the course of the viral infection. However, this association is currently poorly understood. Methods This is a multicenter prospective study of consecutive patients with concomitant COVID-19 and MI who underwent coronary angiography. Quantitative and qualitative coronary angiography were analyzed by two observers in an independent core lab. Results A total of 152 patients were included, of whom 142 (93.4%) had COVID-19 diagnosis confirmation. The median time between symptom onset and hospital admission was 5 (1-10) days. A total of 83 (54.6%) patients presented with ST-elevation MI. The median angiographic Syntax score was 16 (9.0-25.3) and 69.0% had multi-vessel disease. At least one complex lesion was found in 73.0% of patients, 51.3% had a thrombus containing lesion, and 57.9% had myocardial blush grades 0/1. The overall in-hospital mortality was 23.7%. ST-segment elevation MI presentation and baseline myocardial blush grades 0 or 1 were independently associated with a higher risk of death (HR 2.75, 95%CI 1.30-5.80 and HR 3.73, 95%CI 1.61-8.61, respectively). Conclusions Patients who have a MI in the context of ongoing COVID-19 mostly present complex coronary morphologies, implying a background of prior atherosclerotic disease superimposed on a thrombotic milieu. The in-hospital prognosis is poor with a markedly high mortality, prompting further investigation to better clarify this newly described condition.
- Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial(2022) LOPES, Renato D.; GUIMARAES, Patr Icia O.; SCHWARTZ, Gregory G.; BHATT, Deepak L.; BITTNER, Vera A.; BUDAJ, Andrzej; DALBY, Anthony J.; DIAZ, Rafael; GOODMAN, Shaun G.; HARRINGTON, Robert A.; JUKEMA, J. Wouter; KISS, Robert Gabor; LOY, Megan; PORDY, Robert; POULOUIN, Yann; SZAREK, Michael; WHITE, Harvey D.; STEG, Philippe GabrielBACKGROUND: Using data from the ODYSSEY OUTCOMES trial (NCT01663402), we sought to identify factors associated with the development of incident atrial fibrillation in patients with recent acute coronary syndrome without prior atrial fibrillation and to determine whether alirocumab treatment influenced risk of incident atrial fibrillation. METHODS: ODYSSEY OUTCOMES compared alirocumab treatment with placebo in 18,924 patients with recent acute coronary syndrome and dyslipidemia despite high-intensity or maximum-tolerated statin therapy. The primary outcome of major adverse cardiovascular events (MACE) comprised death from coronary heart disease, non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization. Patients were classified as having previous atrial fibrillation (present prior to or at randomization) or no previous atrial fibrillation. A multivariable model was used to determine factors associated with incident atrial fibrillation. RESULTS: Among 18,262 participants without prior atrial fibrillation at baseline, 499 (2.7%) had incident atrial fibrillation during follow-up. Older age, history of heart failure or myocardial infarction, and higher body mass index were significantly associated with incident atrial fibrillation. Treatment with alirocumab or placebo did not influence the cumulative incidence of atrial fibrillation (hazard ratio 0.91; 95% confidence interval, 0.77-1.09). Patients with vs without a history of atrial fibrillation had a higher incidence of MACE (8.8 vs 3.7 events per 100 patient-years), without significant interaction between atrial fibrillation and randomized treatment on risk of MACE (P-interaction =.78). CONCLUSIONS: While alirocumab did not modify risk of incident atrial fibrillation after acute coronary syndrome, it did reduce the risk of MACE, regardless of prior atrial fibrillation history. History of atrial fibrillation is an independent predictor of recurrent cardiovascular events after acute coronary syndrome. (c) 2022 The Authors.
bookPart Utilização de marca-passo transcutâneo(2018) GUIMARãES, Patrícia Oliveira; LAGE, Rony Lopes; SOEIRO, Alexandre de Matos- Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin Insights From the AUGUSTUS Trial(2019) VORA, Amit N.; ALEXANDER, John H.; WOJDYLA, Daniel M.; ARONSON, Ronald; GRANGER, Christopher B.; DARIUS, Harald; WINDECKER, Stephan; MEHRAN, Roxana; AVERKOV, Oleg; BUDAJ, Andrzej; KONG, David F.; KOBALAVA, Zhanna; MEHTA, Rajendra H.; MIRZA, Zulfiqar; GUIMARAES, Patricia Oliveira; PARKHOMENKO, Alexander; QUADROS, Alexandre; THIELE, Holger; GOODMAN, Shaun G.; LOPES, Renato D.
bookPart Aspectos atuais do infarto agudo do miocárdio sem supradesnivelamento do segmento ST(2016) GIRALDEZ, Roberto Rocha C. V.; GUIMARãES, Patrícia Oliveira; SILVA, Guilherme Nunes da; LIMA, Felipe Gallego; GANEM, Fernando; RAMOS, RuiconferenceObject A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin(2023) ONUMA, Yoshinobu; MASUDA, Shinichiro; MURAMATSU, Takashi; ISHIBASHI, Yuki; KOZUMA, Ken; KAWASHIMA, Hideyuki; NAKAZAWA, Gaku; TAKAHASHI, Kuniaki; TANABE, Kengo; KOGAME, Norihiro; NAKAMURA, Masato; ASANO, Taku; OKAMURA, Takayuki; MIYAZAKI, Yosuke; TATEISHI, Hiroki; OZAKI, Yukio; NAKATANI, Shimpei; KATAGIRI, Yuki; MORINO, Yoshihiro; NINOMIYA, Kai; KAGEYAMA, Shigetaka; KOTOKU, Nozomi; GUIMARAES, Patricia O.; LEMOS, Pedro A.; SERRUYS, Patrick W.